BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

11/13/2025

Shanu MD, Breast Medical Oncologist and Attending Physician at MSK, provides insight on the Corporation's collaboration aimed at advancing BriaCell's next-generation personalized immunotherapy into the clinic. https://bit.ly/3JjQRC6

11/11/2025

“We expect the addition of these clinical sites will further accelerate patient enrollment in BriaCell’s pivotal Phase 3 study of Bria-IMT regimen in MBC and support our mission to bring this therapy to patients with significant unmet medical needs,” stated Dr. William V. Williams, BriaCell's President and CEO. Learn more: https://bit.ly/4qle1Zn

11/07/2025

“We look forward to confirming these encouraging preclinical results in planned clinical trials of Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer,” stated Dr. William V. Williams, BriaCell’s President & CEO. For presentation details, please visit: https://bit.ly/49G2QEO

11/07/2025

Chief Scientific Officer, Dr. Miguel Lopez-Lago discusses BriaCell's poster highlighting the next-generation Bria-OTS+ platform. The data demonstrates its rapid, potent and durable anti-cancer activity, achieved by activating both innate and adaptive immune responses. Learn more: https://bit.ly/49G2QEO

11/07/2025

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) is presenting evidence of strong immune system engagement and anti-cancer activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. Find details: https://bit.ly/49G2QEO

Reminder: Tomorrow, November 7th, BriaCell will be presenting preclinical Bria-OTS+ data in a poster presentation at the...
11/06/2025

Reminder: Tomorrow, November 7th, BriaCell will be presenting preclinical Bria-OTS+ data in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. Find details: https://bit.ly/4pQzGIM

11/05/2025

“We will present extensive immune system activation and cytotoxicity data at the upcoming poster session on November 7, 2025,” stated Dr. William V. Williams, BriaCell’s President & CEO. For presentation details, please visit: https://bit.ly/4op7Wde

11/04/2025

Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer, comments on the Company's upcoming poster that emphasizes robust anti-cancer activity of its next generation Bria-OTS+ platform. Learn more: https://bit.ly/4op7Wde

11/04/2025

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) will be showing evidence of strong immune system engagement inducing potent anti-cancer cell activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD. Find details: https://bit.ly/4op7Wde

may be ending, but the fight against continues.At BriaCell, we remain committed to developing novel that aim to tr...
10/31/2025

may be ending, but the fight against continues.

At BriaCell, we remain committed to developing novel that aim to transform cancer care. Learn more about our work: https://bit.ly/4d8P2Sf

10/29/2025

BriaCell's collaboration with MSK starts with manufacturing, IND development and clinical protocol support for a Phase 1 clinical trial with Bria-BRES+, BriaCell’s next generation personalized immunotherapy for patients with breast cancer under the Bria-OTS+ platform. For more information, visit: https://bit.ly/3JjQRC6

In a Phase 2 clinical study of 54 patients, Bria-IMT combination regimen produced robust (~2X longer) overall survival i...
10/28/2025

In a Phase 2 clinical study of 54 patients, Bria-IMT combination regimen produced robust (~2X longer) overall survival in patients versus competitor drugs.

To determine eligibility for participation in BriaCell’s pivotal Phase 3 study in MBC patients, please visit: https://bit.ly/3WRwy2M

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

BriaCell Therapeutics

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell based product candidate derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.